Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00038181 · ClinicalTrials.gov registry record · Phase 2

Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
18
Enrollment target

NCT00038181: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT00038181 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00038181, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
18 participants
Enrollment target

Study Summary

The goal of this clinical research study is to find out whether it is safe to treat patients diagnosed with locally advanced prostate cancer with the drug Thalidomide before removing the tumor (radical retropubic prostatectomy). Researchers also want to learn if Thalidomide can shrink or slow the growth of the prostate cancer before the surgery

Interventions

  • DRUG Thalidomide

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2000-10-05
Est. Completion 2005-11-29
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00038181

The ClinicalTrials.gov registry entry for NCT00038181 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.

NCT00038181 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00038181 about?

NCT00038181 is a clinical study titled "Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer". The goal of this clinical research study is to find out whether it is safe to treat patients diagnosed with locally advanced prostate cancer with the drug Thalidomide before removing the tumor (radical retropubic prostatectomy). Researchers also want to learn if Thalidomide can shrink or slow the g...

What is the current status of trial NCT00038181?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2000-10-05. Estimated completion is 2005-11-29.

What interventions are being tested in trial NCT00038181?

The interventions under investigation include: Thalidomide (DRUG).

Who is sponsoring clinical trial NCT00038181?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.